Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2025 | Story Andre Damons | Photo Supplied
Prof Carolina Pohl-Albertyn
Prof Carlien Pohl-Albertyn is the NRF SARChI Research Chair in Pathogenic Yeasts at the UFS.

A new study by researchers from the University of the Free State (UFS), the National Health Laboratory Service, and the University of Venda has confirmed for the first time that common brown locusts are carriers of pathogenic yeasts that can cause severe infections in humans – especially in people with compromised immune systems or who are seriously ill.

The study, ‘South African brown locusts, Locustana pardalina, hosts fluconazole resistant, Candidozyma (Candida) auris (Clade III)’, highlights for the first time the presence of the pathogenic (disease-producing) fungal yeast C. auris in the digestive tract of the locusts, and shows their potential in disseminating this emerging pathogen. The research started in April 2022, when 20 gregarious (swarming) adult locusts were collected during a large locust outbreak which occurred from September 2021 to May 2022 in the semi-arid Eastern Karoo region in the Eastern Cape. The study is still under peer review.

According to Prof Carlien Pohl-Albertyn, National Research Foundation (NRF) SARChI Research Chair in Pathogenic Yeasts, three C. auris strains were isolated from three different adult locusts, two of which also harboured strains of another potentially pathogenic yeast, Candida orthopsilosis. “The fact that we were able to isolate C. auris from 15% of the sampled locusts, using non-selective media and a non-restrictive temperature of 30°C, may indicate that C. auris is abundant in the locusts and that specific selective isolation is not mandatory,” Prof Pohl-Albertyn said.

“Interestingly, C. auris was isolated from the fore- and hindgut of the locusts. Isolation from the foregut, which is dedicated to food intake and storage, filtering and partial digestion, indicates that C. auris was probably obtained by the locusts via feeding activities. Isolation from the hindgut confirms that C. auris can survive the digestive processes in the midgut and is likely to be released back into the environment via faeces.”

Healthy humans are not at great risk

One of the C. auris strains was studied in more detail. This strain was not resistant to disinfectants but showed decreased susceptibility to the common antifungal drug fluconazole. This is a characteristic of this yeast species and thus not surprising. Most of the emerging pathogenic yeasts show this intrinsic resistance. This highlights the urgent need to discover and develop new antifungal drugs.

Prof Pohl-Albertyn, also a Professor of Microbiology in the UFS Department of Microbiology and Biochemistry, says, “Healthy humans are not at great risk for infection by this yeast and there is currently no proof that ingestion may be harmful to them. This is unfortunately not the case for people with compromised immune systems or who are seriously ill. However, few susceptible people come into direct contact with the locusts in South Africa.”

She added that there are treatment options available, using other antifungal drugs, but C. auris can become resistant to all the currently available antifungal drugs.

Importance of the study

“The fact that locusts are a food source for other animals, such as birds, could lead to eventual distribution of the yeast to people. In other countries, wild locusts are a food source for humans and there more direct transmission may be possible,” Prof Pohl-Albertyn said.

She explained that this study tries to answer questions regarding the natural hosts of this emerging pathogen and how it may facilitate the spread of the pathogen to the rest of the environment. The study is one part of the puzzle regarding how new pathogens may emerge from the environment and spread to people.

“One of the questions in the field of pathogenic yeasts is how C. auris was able to emerge as a pathogen in several different countries in a relatively short period. It is well known as a hospital-acquired pathogen, but it is not known where in the environment it occurs naturally, and which environmental factors may have shaped its evolution and ability to cause human infections. This has implications for the prevention of the spread of this specific yeast species, as well as our preparedness for new pathogenic yeasts that may be emerging from the environment.”

News Archive

UFS staff get salary adjustment of 13,35%
2008-11-13

 

At the signing of the salary agreement were, from the left: Prof. Johan Grobbelaar, Chairperson of UVPERSU, Prof. Teuns Verschoor, Acting Rector of the UFS, and Ms Senovia Welman, Chairperson of NEHAWU.
Photo: Anita Lombard

UFS staff get salary adjustment of 13,35%

The University of the Free State’s (UFS) management and trade unions have agreed on an improvement in the service benefits of staff of 16,55% for 2009. This includes a general salary adjustment of 13,35% (according to the estimated government subsidy that will be received in 2009).

“The negotiating parties agreed that adjustments could vary from a minimum of 13,00%, or more, depending on the government subsidy and the model forecasts. If the minimum of 13,00% is not affordable, the parties will re-negotiate,” said Prof. Teuns Verschoor, Acting Rector of the UFS.

“The negotiations were conducted in a positive spirit and the parties are in agreement that it is an exceptionally good adjustment – being higher than for example the increase in medical premiums,” said Prof. Verschoor.

The agreement was signed yesterday by representatives of the UFS management and the trade unions, UVPERSU and NEHAWU.

An additional once-off non-pensionable bonus of R3 390 will also be paid to staff later this year.

The bonus will be paid to all staff members who were in the employ of the UFS on UFS conditions of service on 10 November 2008 and who assumed duties before 1 October 2008. This includes all former Vista staff, regardless of whether they have already been aligned with UFS conditions of service.


The bonus is payable in recognition of the role played by staff during the year to promote the UFS as a university of excellence and as confirmation of the role and effectiveness of the remuneration model.

“It is important to note that this bonus can be paid due to the favourable financial outcome of 2008,” said Prof. Verschoor.

It is the intention to pass the maximum benefit possible on to staff without exceeding the limits of financial sustainability of the institution. For this reason, the negotiating parties reaffirmed their commitment to the Multiple-year Income-related Remuneration Improvement Model used as a framework for negotiations. The model and its applications are unique and has as a point of departure that the UFS must be and remain financially sustainable.

Additional funding (0,70%) was also negotiated. This will be allocated on 1 January 2009 to accelerate the phasing-in of medical benefits and, if possible, to finalise the phasing-in process. Agreement was reached that 2,50% will be allocated for growth in capacity building to ensure that provision is made for the growth of the UFS over the last few years, as well as the incorporation of Vista staff.

The agreement also applies to all staff members of the two above-mentioned campuses whose conditions of employment have already been aligned with those of the Main Campus.

The implementation date for the salary adjustment is 1 January 2009. The adjustment will be calculated on the total remuneration package.

In 2008, a total improvement of service benefits of 9,32% and a salary adjustment of 7,52% were paid to employees. Staff received a once-off non-pensionable bonus of R3 000 at the end of 2007.

Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
12 November 2007
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept